BridgeMD
Darolutamide vs ADT in hormone naïve Pca
EU CTIS ID: 2024-510840-30-00
What this study is testing
The primary trial objective is to demonstrate that darolutamide produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥ 80% reduction compared to baseline) that are in the range of those achieved with 24 weeks of ADT.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Aged 18 years or older
- Able to swallow the study drug whole as a tablet
- Adequate bone marrow function • absolute neutrophil count (ANC) ≥ 1.5 109/L. • hemoglobin ≥ 10.0 g/dl. • platelets ≥ 100 109/L.
- Adequate renal function: creatinine ≤ 1.5 x ULN
- Albumin > 25 g/L
- Adequate hepatic function: • Bilirubin: total bilirubin ≤ 1.5 × upper limit of normal (ULN). • AST and/or ALT ≤ 2.5 × ULN.
You likely can't join if
- Previously or currently receiving hormonal therapy with intent to treat prostate cancer disease (surgical castration or other hormonal manipulation, e.g. LHRH agonists, LHRH antagonists, anti-androgens, oestrogens, 5α-reductase inhibitor). For patients that have received (neo)adjuvant ADT before radiotherapy, it should have been stopped for more than 1 year
- History of prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer from which the patient has been disease-free for a period of at least 5 years.
- Clinically significant cardiovascular disease including: • Myocardial infarction within 6 months prior to randomization • Uncontrolled angina within 3 months prior to randomization • Coronary/peripheral artery bypass within 6 months prior to randomization • Stroke within 6 months prior to randomization • Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months results in a left ventricular ejection fraction that is ≥ 45% • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes) • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
- Uncontrolled hypertension as indicated by a resting systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at the screening visit
- Prior use of investigational agents that block androgen synthesis or block androgen receptor
- Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g. saw palmetto)
See the full eligibility criteria
Who can join
- Aged 18 years or older
- Able to swallow the study drug whole as a tablet
- Adequate bone marrow function • absolute neutrophil count (ANC) ≥ 1.5 109/L. • hemoglobin ≥ 10.0 g/dl. • platelets ≥ 100 109/L.
- Adequate renal function: creatinine ≤ 1.5 x ULN
- Albumin > 25 g/L
- Adequate hepatic function: • Bilirubin: total bilirubin ≤ 1.5 × upper limit of normal (ULN). • AST and/or ALT ≤ 2.5 × ULN.
- Normal 12-lead ECG as per local standard
- Patients of reproductive potential should use adequate birth control measures, during the study treatment period and for at least 3 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
- Histologically confirmed prostate cancer (all stages) for whom continuous ADT is indicated for a minimum period of 24 weeks
- M0 patients or those presenting with a maximum of 4 confirmed metastatic lesions, including bone, extra-pelvic lymph nodes, and > 2 cm pelvic lymph nodes by imaging (contrast enhanced CT scans or MRI, Tc-99m BS according to local practice, see section 6.1.1). Visceral metastases are excluded
- Asymptomatic for metastatic prostate cancer; urinary symptoms are allowed
- Baseline total testosterone ≥ 8 nmol/L or 230 ng/dL
- Two subsequent PSA values ≥ 2 ng/ml, done in the past 3 months (prior to enrollment) with a minimum of 2 weeks between the two, with the second being equal to or higher than the first
- WHO performance status (PS) of 0-1
- G8 score ≥ 14 for patients aged ≥ 70 years old
- A life expectancy of at least 12 months
What rules you out
- Previously or currently receiving hormonal therapy with intent to treat prostate cancer disease (surgical castration or other hormonal manipulation, e.g. LHRH agonists, LHRH antagonists, anti-androgens, oestrogens, 5α-reductase inhibitor). For patients that have received (neo)adjuvant ADT before radiotherapy, it should have been stopped for more than 1 year
- History of prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer from which the patient has been disease-free for a period of at least 5 years.
- Clinically significant cardiovascular disease including: • Myocardial infarction within 6 months prior to randomization • Uncontrolled angina within 3 months prior to randomization • Coronary/peripheral artery bypass within 6 months prior to randomization • Stroke within 6 months prior to randomization • Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months results in a left ventricular ejection fraction that is ≥ 45% • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes) • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
- Uncontrolled hypertension as indicated by a resting systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at the screening visit
- Prior use of investigational agents that block androgen synthesis or block androgen receptor
- Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g. saw palmetto)
- Has received systemic glucocorticoids within 24 weeks prior to enrollment or is expected to require systemic glucocorticoids during the study period, unless determined to be medically necessary by the investigator for other indications than prostate cancer
- Radiation therapy for treatment of the primary tumor within 3 months prior to enrollment
- Use of an investigational agent within 4 weeks prior to enrollment is not allowed
- Gastrointestinal disorder affecting absorption (e.g. gastrectomy, active peptic ulcer disease) within 3 months prior to enrollment
- Known hypersensitivity to the study treatment or any of its ingredients (refer to Investigator's brochure).
- Severe or uncontrolled concurrent disease, infection or co-morbidity including active viral hepatitis, known human immunodeficiency virus infection with detectable viral load (HIV) or chronic liver disease (Child Pugh C)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.